GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Dec 1, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 1, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on December 1, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing details a transaction in the company's own shares.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, a common corporate action.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker
- 31¼ pence (dollar_amount) — Nominal value of ordinary shares
FAQ
What specific number of GSK plc ordinary shares were purchased?
The filing states that a 'following number' of ordinary shares were purchased, but the exact quantity is not specified in the provided text.
Who acted as the broker for this transaction?
BNP Paribas SA acted as the broker for the purchase of GSK plc's ordinary shares.
What is the nominal value of GSK plc's ordinary shares?
The nominal value of GSK plc's ordinary shares is 31¼ pence each.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Does GSK plc file annual reports under Form 20-F?
Yes, the filing indicates with an 'X' that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 3,068 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-12-01 06:54:20
Filing Documents
- a5288j.htm (6-K) — 2856KB
- 0001654954-25-013521.txt ( ) — 2857KB
From the Filing
IN OWN SHARES a5288j UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of December 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 28 November 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 250,000 Lowest price paid per share (GBp): 1,786.00p Highest price paid per share (GBp): 1,809.50p Volume-weighted average price paid per share (GBp): 1,799.00p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 11,143,733 ordinary shares.   Following the above purchase, the Company will hold 236,608,577 ordinary shares in treasury and have 4,078,825,107 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,078,825,107. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.80 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:    GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     28 November 2025 Investment firm:      BNP Paribas SA     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   35,749   1,809.00p   1,786.00p   1,798.32p   CHIX   72,569   1,809.00p   1,786.00p   1,799.12p   XLON   141,682   1,809.50p   1,786.00p   1,799.11p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   117   1806.0   CHIX   28-Nov-2025   08:00:45   20251128156226796   197   1806.0   XLON   28-Nov-2025   08:00:45   20251128156226798   74   1806.5   CHIX   28-Nov-2025   08:02:05   20251128156227145   35   1806.5   CHIX   28-Nov-2025   08:02:05   20251128156227147   197